Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.
Abbott India financials and key ratios
Figures from the company's filings with NSE
In FY26 its consolidated net profit was ₹1,552 crore on revenue of ₹6,929 crore.
Latest balance sheet
31 March 2026
Abbott India at a glance · consolidated
ROE (FY26)
34.5%−1.2 pts vs FY25ROCE 38.1%
Net worth
₹4,774 Cr31 March 2026
Free cash flow (FY26)
₹1,319 Cr+30.4% vs FY25
Questions
What is the Abbott India net worth?
Abbott India's net worth — shareholders' equity in its consolidated balance sheet — was ₹4,774 crore on 31 March 2026.
What is the Abbott India dividend in 2026 and its record date?
In 2026, Abbott India has declared one dividend: ₹656 (special) with record date 24 July 2026.
What is the Abbott India free cash flow?
In FY26, Abbott India generated ₹1,319 crore of cash from operations and spent ₹0 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹1,319 crore. In FY25 it was ₹1,012 crore.
What is the Abbott India ROE and ROCE?
In FY26, Abbott India's return on equity (ROE) was 34.5% and its return on capital employed (ROCE) was 38.1%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 35.7% and ROCE 38.8%.
What is the Abbott India revenue and profit in FY26?
In FY26 (April 2025–March 2026), Abbott India's consolidated net profit was ₹1,552 crore, up 9.7% from ₹1,414 crore in FY25, on revenue from operations of ₹6,929 crore (up 8.1%). Over three years, from FY23, net profit was up 63.5%.
Abbott India vs Pfizer: how do they compare?
In FY26, Abbott India earned net profit of ₹1,552 crore on revenue of ₹6,929 crore, against ₹722 crore on ₹2,520 crore for Pfizer. Abbott India's operating margin was 26.2% (Pfizer 33.6%) and its return on equity 34.5% (Pfizer 17.2%).
How does Abbott India compare with its peers?
On FY26 consolidated figures, against Pfizer, Glaxosmithkline Pharmaceuticals and Ipca Laboratories: Abbott India's operating margin of 26.2% is the third highest of the four (Pfizer 33.6%, Glaxosmithkline Pharmaceuticals 32.5%, Ipca Laboratories 16.2%; peer average 27.4%); its return on equity of 34.5% is the second highest of the four (Pfizer 17.2%, Glaxosmithkline Pharmaceuticals 49.1%, Ipca Laboratories 15.2%; peer average 27.2%); its revenue growth over three years of 9.0% a year is the second highest of the four (Pfizer 1.3% a year, Glaxosmithkline Pharmaceuticals 5.5% a year, Ipca Laboratories 15.6% a year; peer average 7.5% a year).
Where do these Abbott India figures come from?
From Abbott India's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
